関節リウマチ治療改善につながる新たな炎症経路を特定 (Study Identifies Alternate Path for Inflammation That Could Improve RA Treatment)

ad

2026-01-30 ワシントン州立大学(WSU)

米ワシントン州立大学(WSU)の研究チームは、関節リウマチ(RA)治療の改善につながる可能性のある新たな炎症経路を特定した。RAは自己免疫反応によって慢性的な炎症と関節破壊を引き起こす疾患で、既存治療の一部患者では十分な効果が得られないことが課題となっている。本研究では、従来重視されてきた炎症シグナルとは異なる「代替的炎症経路」が、関節内の免疫応答や組織損傷に関与していることを明らかにした。この経路を制御することで、炎症を抑えつつ免疫機能全体への副作用を軽減できる可能性が示された。研究者らは、この知見がRAに対する新規作用機序の治療薬開発につながり、難治例への治療選択肢拡大に貢献するとしている。

<関連情報>

TWEAK受容体(Fn14)は、関節リウマチ滑膜線維芽細胞におけるTNF-α誘発炎症を増悪させ、抗TNF-α療法への反応に影響を与える TWEAK receptor (Fn14) exacerbates TNF-α-induced inflammation in rheumatoid arthritis synovial fibroblasts and influences response to anti-TNF-α therapy

Farheen S. Shaikh,Meena A. Shanta,Anil K. Singh,Alexis M. Daniels,Sadik A. Khuder,Geoffrey M. Thiele,George W. Reed,Joel M. Kremer,Dimitrios A. Pappas,Jeffrey R. Curtis,James R. O’Dell,Madhu M. Ouseph,David A. Fox & Salahuddin Ahmed
Cellular & Molecular Immunology  Published:30 January 2026
DOI:https://doi.org/10.1038/s41423-026-01386-y

関節リウマチ治療改善につながる新たな炎症経路を特定 (Study Identifies Alternate Path for Inflammation That Could Improve RA Treatment)

Abstract

The use of TNF inhibitors (TNFis) has revolutionized the management of rheumatoid arthritis (RA) and other autoimmune conditions, but some patients remain resistant to TNFis, for which the molecular mechanisms remain elusive. Our study reveals novel molecular crosstalk between TWEAK/Fn14 and TNF-α signaling and its potential implications for therapy resistance. Elevated Fn14 expression was observed in human synovial tissues and joint homogenates from adjuvant-induced arthritis rats. Low doses of TNF-α and TWEAK synergistically induced inflammation in human RA synovial fibroblasts (RASFs). Furthermore, increased expression of the TWEAK receptor (Fn14) was sufficient for TNF-α to synergistically induce RANTES/CCL5 and MMP-1. In contrast, Fn14 knockdown suppressed the expression of TNF-α-induced adhesion molecules (PDPN, ICAM-1, VCAM-1, and cadherin-11) and inflammatory chemokines (MCP-1/CCL2, RANTES/CCL5, IL-8/CXCL8, and ITAC/CXCL11). Blocking Fn14 with an antagonist (L524-0366) suppressed TNF-α-induced phosphorylation of the kinases JNK, p38, and PKCδ and consequently decreased MCP-1/CCL2, RANTES/CCL5, ITAC/CXCL11, and MMP-1 production. RNA-sequencing analysis revealed >200 differentially expressed genes significantly affected by Fn14 knockdown in TNF-α-activated RASFs. Gene set enrichment analysis (GSEA) revealed significant enrichment of IFN-α and IFN-γ pathway responses in the NC siRNA/TNF-α group compared with the Fn14 siRNA/TNF-α group. Administration of L524-0366 (10 mg/kg) intraperitoneally daily from the onset of disease ameliorated collagen antibody-induced arthritis in mice. These findings reveal that TNF-α utilizes the TWEAK/Fn14 axis to induce inflammation, suggesting the potential benefits of targeting TWEAK/Fn14 as an adjunct therapy with TNF inhibitors.

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました